Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience

Published:2024-08-13 Issue:5 Volume:30 Page:1247-1249
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Klamroth Robert¹²³^ORCID,Gottstein Saskia¹

Affiliation:

1. Vivantes Clinic in Friedrichshain Internal Medicine Vascular Medicine and Haemostaseology Berlin Germany

2. Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty University of Bonn Bonn Germany

3. Medical Faculty University of Bonn Bonn Germany

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.15086

Reference11 articles.

1. First conditional marketing authorization approval in the European Union for hemophilia “A” gene therapy

2. Hemophilia Gene Therapy: The End of the Beginning?

3. Gene therapy for hemophilia

4. WFH Guidelines for the Management of Hemophilia, 3rd edition

5. Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP